Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial

To determine the maximum tolerated dose (MTD) of stereotactic ablative radiation therapy (SABR) in combination with immunotherapy for the treatment of patients with metastatic melanoma. The study also investigates the effects of timing and dosing of SABR on clinical efficacy.

Source: International Journal of Radiation Oncology * Biology * Physics - May 20, 2020 Category: Radiology Authors: Gishan Ratnayake, Simone Reinwald, Mark Shackleton, Maggie Moore, Mark Voskoboynik, Jeremy Ruben, Menno C. van Zelm, Di Yu, Rachel Ward, Robin Smith, Andrew Haydon, Sashendra Senthi Tags: Clinical Results of Immune Therapy and Radiation Source Type: research